Magle Chemoswed

As part of this collaboration, Magle PharmaCept will contribute to the Treatment Opportunities for Pancreatic Cancer project, running from 2025 to 2026. The initiative is designed to improve patient outcomes by expanding access to treatment solutions and enhancing surgical care within the pancreatic cancer community. The scope of this work stream aims to present innovations in treatment and to communicate best practices and essential requirements for the quality of patient care. The activities are addressed to patients, patient carers, patient advocates, healthcare staff, and other stakeholders.

"Pancreatic Cancer Europe (PCE) is honoured to begin this new collaboration with Magle for the benefit of pancreatic cancer patients and their families. Magle supports PCE's activities that aim to increase patients' awareness on pancreatic cancer, to enhance their quality of life. I hope that this important partnership will grow over time". Said Maria Luisa Pagano, PCE Secretariat Coordinator.

This joint effort underscores Magle PharmaCept’s commitment to bringing life-changing innovation for patients. At Magle PharmaCept, patients come first—we provide advanced medical solutions that transform lives and contribute to the progress of global healthcare through targeted partnerships and innovation.

“This partnership with PCE marks a meaningful step in our aspiration to support healthcare professionals and patients navigating modern pancreatic cancer surgery. “ said Helena Ossmer Thedius, Chief Marketing and Innovation Officer at Magle Group.